^
    Back
    Association details:
    Biomarker:TMB-H
    Cancer:Solid Tumor
    Drug:invikafusp alfa (STAR0602) (Vβ TCR stimulant, Vβ10 TCR stimulant, Vβ6 TCR stimulant)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants with Advanced Solid Tumors

    Excerpt:
    ...High mutational burden (TMB-H) 2....
    Trial ID:
    START-001
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    SITC 2022
    Title:

    Preclinical evaluation of STAR0602, a novel, first-in-class anti-TCR Vb targeted bispecific antibody with potent anti-tumor activity for PD-1 refractory solid tumors

    Published date:
    11/08/2022
    Excerpt:
    In PD1 refractory human and murine tumor models with a high TMB, STAR0602 and mSTAR0602 induce potent anti-tumor activity as monotherapy, mediated by selective expansion of Vb CD8+ memory T cells. 
    DOI:
    10.1136/jitc-2022-SITC2022.1337